Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Perspective

I don't know LL The PR says $9.7 million compared to $19.9 million in the prior year for PDS. Which seems to coincide with the balance sheet.

I also see some jiggery pokery in the PDS "licenses receivable" that makes me wonder if the Sanyo license earnings were taken as profits this year. (Sanyo was declared June 2)

I didn't see anything in subsequent events however.

Share
New Message
Please login to post a reply